Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TGTX |
---|---|---|
09:32 ET | 19286 | 16.89 |
09:34 ET | 5666 | 16.74 |
09:36 ET | 12415 | 16.76 |
09:38 ET | 2870 | 16.75 |
09:39 ET | 3835 | 16.85 |
09:41 ET | 6400 | 16.95 |
09:43 ET | 14120 | 17 |
09:45 ET | 6796 | 17.0699 |
09:48 ET | 10196 | 17.02 |
09:50 ET | 7144 | 16.91 |
09:52 ET | 4411 | 17.01 |
09:54 ET | 6210 | 17.07 |
09:56 ET | 42685 | 16.92 |
09:57 ET | 2388 | 16.88 |
09:59 ET | 14766 | 16.81 |
10:01 ET | 15084 | 16.87 |
10:03 ET | 9917 | 16.92 |
10:06 ET | 20203 | 16.98 |
10:08 ET | 3377 | 16.96 |
10:10 ET | 1350 | 16.9 |
10:12 ET | 3548 | 16.91 |
10:14 ET | 3208 | 16.93 |
10:15 ET | 4503 | 16.9 |
10:17 ET | 10587 | 16.92 |
10:19 ET | 10533 | 16.95 |
10:21 ET | 3832 | 16.9 |
10:24 ET | 14827 | 16.88 |
10:26 ET | 1500 | 16.89 |
10:28 ET | 4486 | 16.88 |
10:30 ET | 200 | 16.91 |
10:32 ET | 4728 | 16.85 |
10:33 ET | 4475 | 16.85 |
10:35 ET | 1724 | 16.83 |
10:37 ET | 2170 | 16.83 |
10:39 ET | 7482 | 16.85 |
10:42 ET | 1279 | 16.8 |
10:44 ET | 10719 | 16.81 |
10:46 ET | 1299 | 16.825 |
10:48 ET | 1300 | 16.83 |
10:50 ET | 1248 | 16.825 |
10:51 ET | 3250 | 16.805 |
10:53 ET | 1730 | 16.81 |
10:55 ET | 704 | 16.81 |
10:57 ET | 57191 | 16.81 |
11:00 ET | 5624 | 16.81 |
11:02 ET | 3588 | 16.88 |
11:04 ET | 4780 | 16.9075 |
11:06 ET | 2304 | 16.85 |
11:08 ET | 1934 | 16.85 |
11:09 ET | 1793 | 16.8376 |
11:11 ET | 3417 | 16.78 |
11:13 ET | 6153 | 16.78 |
11:15 ET | 2250 | 16.79 |
11:18 ET | 900 | 16.8 |
11:20 ET | 100 | 16.81 |
11:22 ET | 1180 | 16.81 |
11:24 ET | 1800 | 16.8 |
11:26 ET | 3164 | 16.81 |
11:27 ET | 531 | 16.82 |
11:29 ET | 5234 | 16.82 |
11:31 ET | 218 | 16.82 |
11:33 ET | 300 | 16.81 |
11:36 ET | 1007 | 16.82 |
11:38 ET | 4544 | 16.79 |
11:40 ET | 1462 | 16.78 |
11:42 ET | 2903 | 16.78 |
11:44 ET | 5098 | 16.77 |
11:45 ET | 1503 | 16.7718 |
11:47 ET | 1708 | 16.76 |
11:49 ET | 8469 | 16.78 |
11:51 ET | 2200 | 16.7701 |
11:54 ET | 6780 | 16.75 |
11:56 ET | 8249 | 16.7528 |
11:58 ET | 1949 | 16.75 |
12:00 ET | 753 | 16.73 |
12:02 ET | 1300 | 16.72 |
12:03 ET | 3829 | 16.705 |
12:05 ET | 3292 | 16.72 |
12:07 ET | 200 | 16.715 |
12:09 ET | 6935 | 16.74 |
12:12 ET | 3065 | 16.76 |
12:14 ET | 1937 | 16.75 |
12:16 ET | 300 | 16.75 |
12:18 ET | 600 | 16.74 |
12:20 ET | 3008 | 16.7204 |
12:21 ET | 6949 | 16.72 |
12:23 ET | 1600 | 16.69 |
12:25 ET | 1300 | 16.69 |
12:27 ET | 1921 | 16.69 |
12:30 ET | 5417 | 16.6703 |
12:32 ET | 4274 | 16.7 |
12:34 ET | 900 | 16.6806 |
12:36 ET | 12895 | 16.67 |
12:38 ET | 1761 | 16.7 |
12:39 ET | 200 | 16.69 |
12:41 ET | 2899 | 16.685 |
12:43 ET | 306 | 16.695 |
12:45 ET | 477 | 16.71 |
12:48 ET | 900 | 16.73 |
12:50 ET | 100 | 16.71 |
12:52 ET | 2884 | 16.725 |
12:54 ET | 300 | 16.725 |
12:56 ET | 17357 | 16.72 |
12:57 ET | 18513 | 16.8081 |
12:59 ET | 4400 | 16.81 |
01:01 ET | 4662 | 16.83 |
01:03 ET | 2000 | 16.81 |
01:06 ET | 5450 | 16.8001 |
01:08 ET | 1128 | 16.8 |
01:10 ET | 600 | 16.8 |
01:12 ET | 1069 | 16.8 |
01:14 ET | 2000 | 16.76 |
01:15 ET | 7211 | 16.74 |
01:17 ET | 500 | 16.76 |
01:19 ET | 1153 | 16.76 |
01:21 ET | 800 | 16.76 |
01:24 ET | 200 | 16.76 |
01:26 ET | 2358 | 16.759 |
01:28 ET | 1178 | 16.75 |
01:30 ET | 911 | 16.75 |
01:32 ET | 1102 | 16.755 |
01:33 ET | 2048 | 16.765 |
01:35 ET | 100 | 16.765 |
01:37 ET | 3733 | 16.75 |
01:39 ET | 5121 | 16.76 |
01:42 ET | 2781 | 16.76 |
01:44 ET | 4236 | 16.83 |
01:46 ET | 8512 | 16.79 |
01:48 ET | 1485 | 16.79 |
01:50 ET | 2921 | 16.81 |
01:51 ET | 3853 | 16.82 |
01:53 ET | 14815 | 16.81 |
01:55 ET | 2049 | 16.8 |
01:57 ET | 2194 | 16.8195 |
02:00 ET | 3342 | 16.81 |
02:02 ET | 600 | 16.8 |
02:04 ET | 6911 | 16.83 |
02:06 ET | 4477 | 16.78 |
02:08 ET | 872 | 16.795 |
02:09 ET | 2236 | 16.785 |
02:11 ET | 852 | 16.77 |
02:13 ET | 872 | 16.77 |
02:15 ET | 1000 | 16.76 |
02:18 ET | 3013 | 16.76 |
02:20 ET | 704 | 16.762 |
02:22 ET | 5298 | 16.78 |
02:24 ET | 2139 | 16.77 |
02:26 ET | 676 | 16.7842 |
02:27 ET | 1930 | 16.775 |
02:29 ET | 5906 | 16.81 |
02:31 ET | 1628 | 16.81 |
02:33 ET | 815 | 16.81 |
02:36 ET | 400 | 16.82 |
02:38 ET | 9049 | 16.82 |
02:40 ET | 1062 | 16.8 |
02:42 ET | 1679 | 16.8 |
02:44 ET | 1569 | 16.81 |
02:45 ET | 500 | 16.82 |
02:47 ET | 500 | 16.81 |
02:49 ET | 2456 | 16.8 |
02:51 ET | 315 | 16.81 |
02:54 ET | 2256 | 16.81 |
02:56 ET | 1044 | 16.8 |
02:58 ET | 2000 | 16.8 |
03:00 ET | 5619 | 16.76 |
03:02 ET | 4455 | 16.74 |
03:03 ET | 7489 | 16.755 |
03:05 ET | 4354 | 16.77 |
03:07 ET | 2554 | 16.82 |
03:09 ET | 2059 | 16.82 |
03:12 ET | 350 | 16.8199 |
03:14 ET | 12227 | 16.805 |
03:16 ET | 6499 | 16.73 |
03:18 ET | 10705 | 16.77 |
03:20 ET | 12535 | 16.78 |
03:21 ET | 1000 | 16.79 |
03:23 ET | 6447 | 16.82 |
03:25 ET | 9552 | 16.83 |
03:27 ET | 4015 | 16.82 |
03:30 ET | 1971 | 16.82 |
03:32 ET | 5403 | 16.77 |
03:34 ET | 3717 | 16.78 |
03:36 ET | 4047 | 16.765 |
03:38 ET | 23199 | 16.77 |
03:39 ET | 1511 | 16.78 |
03:41 ET | 7437 | 16.79 |
03:43 ET | 2980 | 16.775 |
03:45 ET | 4058 | 16.785 |
03:48 ET | 7603 | 16.765 |
03:50 ET | 5115 | 16.7775 |
03:52 ET | 8678 | 16.765 |
03:54 ET | 9532 | 16.79 |
03:56 ET | 9712 | 16.8 |
03:57 ET | 14186 | 16.79 |
03:59 ET | 52810 | 16.76 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
TG Therapeutics Inc | 2.6B | 76.0x | --- |
ADMA Biologics Inc | 2.5B | -528.4x | --- |
Twist Bioscience Corp | 3.1B | -15.5x | --- |
Arrowhead Pharmaceuticals Inc | 3.2B | -6.3x | --- |
MorphoSys AG | 2.8B | -5.4x | --- |
Vericel Corp | 2.1B | 4,534.5x | --- |
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
---|---|
Revenue (TTM) | $289.3M |
Shares Outstanding | 154.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.22 |
EPS | $0.22 |
Book Value | $1.06 |
P/E Ratio | 76.0x |
Price/Sales (TTM) | 9.0 |
Price/Cash Flow (TTM) | 62.8x |
Operating Margin | 16.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.